All Updates

All Updates

icon
Filter
Partnerships
Ro and Eli Lilly partner to provide discounted Zepbound weight loss medication
Telehealth
Dec 12, 2024
This week:
Product updates
Pimax announces compact Dream Air VR headset for USD 1,900
Extended Reality
Dec 23, 2024
Funding
HuLoop raises Series A funding from Mighty Capital
Workflow Automation Platforms
Dec 23, 2024
M&A
Fiserv to acquire Payfare for undisclosed sum to enhance embedded finance solutions
Financial Wellness Tools
Dec 23, 2024
M&A
Fiserv to acquire Payfare for undisclosed sum to enhance embedded finance solutions
FinTech Infrastructure
Dec 23, 2024
Funding
Meight raises EUR 3.4 million in funding led by Cusp Capital
Smart Mobility Information
Dec 23, 2024
Regulation/policy
Desktop Metal sues Nano Dimension over merger compliance
Additive Manufacturing
Dec 23, 2024
Management news
Nexa3D scales back operations amid financial crisis
Additive Manufacturing
Dec 23, 2024
Funding
Fraction AI raises USD 6 million in pre-seed funding to scale hybrid data labeling
Machine Learning Infrastructure
Dec 23, 2024
Last week:
Partnerships
Rocket Lab launches sixth Synspective radar satellite as part of ongoing partnership
Space Travel and Exploration Tech
Dec 21, 2024
Partnerships
EHang partners with Changan Automobile to develop eVTOL aircraft for personal transportation
Passenger eVTOL Aircraft
Dec 21, 2024
Dec 12, 2024

Ro and Eli Lilly partner to provide discounted Zepbound weight loss medication

Partnerships

  • Telehealth company Ro has partnered with pharmaceutical company Eli Lilly to expand distribution of single-dose vials of its GLP-1 weight loss medication Zepbound at reduced prices.

  • Through this partnership, Ro's platform will offer 2.5 mg vials of Zepbound for USD 399 per month and five mg vials for USD 549 per month, matching prices previously only available through LillyDirect. The collaboration allows Lilly to reach Ro's established network of 1.5 million patients, while Ro gains the ability to offer FDA-approved Zepbound instead of solely relying on compounded versions of the medication.

  • Analyst QuickTake: In May , Ro launched an interactive tool called the "GLP-1 Supply Tracker" to offer patients timely information regarding GLP-1 drug availability in their local areas. With this partnership with Eli Lilly, Ro furthers its ability to offer GLP-1 medications while furthering its market presence in the weight loss medication vertical.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.